The 2020 World Congress on Controversies in Multiple Myeloma (COMy) will be held virtually, on October 3–4. Experts in the field came together online to discuss and debate the latest controversies in the field.

Explore all the latest updates below!

COMy 2020

COMy 2020

The 2020 World Congress on Controversies in Multiple Myeloma (COMy) will be held virtually, on October 3–4. Experts in the field came together online to discuss and debate the latest controversies in the field.

Explore all the latest updates below!

New therapeutic options for tailored and selective treatment of multiple myeloma 3:48
New therapeutic options for tailored and selective treatment of multiple myeloma
Paul Richardson
The importance of tailored treatment approach in multiple myeloma 5:33
The importance of tailored treatment approach in multiple myeloma
Paul Richardson
Updates on the HORIZON study: melflufen in R/R multiple myeloma 8:20
Updates on the HORIZON study: melflufen in R/R multiple myeloma
Paul Richardson
Treating GvHD with proteasome inhibitors 3:43
Treating GvHD with proteasome inhibitors
Arnon Nagler
The importance of MRD in multiple myeloma management 1:15
The importance of MRD in multiple myeloma management
Jesús San Miguel
Using MRD to guide treatment decisions in the clinic 1:27
Using MRD to guide treatment decisions in the clinic
Jesús San Miguel
Treatment approaches for fit and frail multiple myeloma patients 1:30
Treatment approaches for fit and frail multiple myeloma patients
Jesús San Miguel
The importance of early diagnosis for improved light chain amyloidosis survival 2:41
The importance of early diagnosis for improved light chain amyloidosis survival
Giampaolo Merlini
Management of AL amyloidosis: what’s new? 4:48
Management of AL amyloidosis: what’s new?
Giampaolo Merlini
The second COMy meeting of the year: new multiple myeloma data 1:03
The second COMy meeting of the year: new multiple myeloma data
Saad Usmani
COMy 2020 highlights: smoldering myeloma, MRD and immunotherapy 7:32
COMy 2020 highlights: smoldering myeloma, MRD and immunotherapy
Arnon Nagler
CD38: a promising target for multiple myeloma antibody therapy 4:52
CD38: a promising target for multiple myeloma antibody therapy
Saad Usmani
The future of immunotherapies for multiple myeloma 4:38
The future of immunotherapies for multiple myeloma
Luciano Costa
Myeloma XI trial: areas for further research 2:55
Myeloma XI trial: areas for further research
Graham Jackson
Refractory multiple myeloma: analyzing MAMMOTH and STORM 3:05
Refractory multiple myeloma: analyzing MAMMOTH and STORM
Luciano Costa
The importance of treating multiple myeloma patients during the COVID-19 pandemic 2:36
The importance of treating multiple myeloma patients during the COVID-19 pandemic
Graham Jackson
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals